Suzuki Ayako, Lymp James, Donlinger Jessica, Mendes Flavia, Angulo Paul, Lindor Keith
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Clin Gastroenterol Hepatol. 2007 Feb;5(2):259-64. doi: 10.1016/j.cgh.2006.09.031. Epub 2006 Dec 15.
BACKGROUND & AIMS: Although hepatocellular carcinoma (HCC) occurs with increased frequency in patients with primary biliary cirrhosis (PBC), the exact frequency is relatively low. Optimal selection of PBC patients for HCC screening needs to be determined for effective screening. In this study, we aimed to explore clinical predictors of HCC in PBC patients.
We performed a case-control study using 17 PBC patients with HCC identified from 1976 to 2002 at the Mayo Clinic. Control PBC patients who had no evidence of HCC were selected for each case by matching the first year of their visit to the Mayo Clinic. All medical information was collected within 2 years from when the cases were diagnosed with HCC. Logistic regression models were used for the analyses.
Age, sex, history of blood transfusion, current smoking, histologic stage at PBC diagnosis, any signs of portal hypertension, Mayo score, hemoglobin level, platelet count, aspartate aminotransferase level, and albumin level were associated with the presence of HCC (P < .05 for each). In multivariable analysis, older age (OR, 1.7; 95% confidence interval [CI], 1.1-2.5 for 5 years), male sex (OR, 9.7; 95% CI, 1.4-68.3), history of blood transfusion (OR, 5.0; 95% CI, 1.0-24.3), and any signs of portal hypertension (OR, 22.9; 95% CI, 3.4-155.3) were associated significantly with increased odds of HCC and yielded an excellent diagnostic performance (area under the receiver operating characteristics curve rate, 0.91).
Older age, male sex, history of blood transfusion, and any signs of portal hypertension or cirrhosis indicate higher likelihood of HCC and should be considered for HCC screening. Further studies in larger patient cohorts are required to verify the diagnostic model.
尽管原发性胆汁性肝硬化(PBC)患者中肝细胞癌(HCC)的发生率有所增加,但确切发生率相对较低。为了进行有效的筛查,需要确定PBC患者进行HCC筛查的最佳选择。在本研究中,我们旨在探索PBC患者发生HCC的临床预测因素。
我们进行了一项病例对照研究,使用了1976年至2002年在梅奥诊所确诊的17例PBC合并HCC患者。通过匹配首次就诊梅奥诊所的年份,为每个病例选择无HCC证据的对照PBC患者。所有医疗信息均在病例被诊断为HCC后的2年内收集。采用逻辑回归模型进行分析。
年龄、性别、输血史、当前吸烟情况、PBC诊断时的组织学分期、门静脉高压的任何体征、梅奥评分、血红蛋白水平、血小板计数、天冬氨酸转氨酶水平和白蛋白水平均与HCC的存在相关(每项P < 0.05)。在多变量分析中,年龄较大(比值比[OR],1.7;95%置信区间[CI],5年时为1.1 - 2.5)、男性(OR,9.7;95% CI,1.4 - 68.3)、输血史(OR,5.0;95% CI,1.0 - 24.3)和门静脉高压的任何体征(OR,22.9;95% CI,3.4 - 155.3)与HCC发生几率的增加显著相关,并且具有出色的诊断性能(受试者工作特征曲线下面积率,0.91)。
年龄较大、男性、输血史以及门静脉高压或肝硬化的任何体征表明发生HCC的可能性较高,应考虑进行HCC筛查。需要在更大的患者队列中进行进一步研究以验证该诊断模型。